Private Advisor Group’s Citius Pharmaceuticals CTXR Stock Holding History

Private Advisor Group’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,600	Closed	-$20K	–	2329
2024 Q3	$20K	Sell	1,600 -1	-0.1%	-$17	﹤0.01%	2374
2024 Q2	$23.4K	Buy	1,601 +1	+0.1%	+$18	﹤0.01%	2293
2024 Q1	$35.9K	Hold	1,600	–	–	﹤0.01%	2254
2023 Q4	$30.3K	Hold	1,600	–	–	﹤0.01%	2178
2023 Q3	$27.4K	Hold	1,600	–	–	﹤0.01%	2081
2023 Q2	$48K	Hold	1,600	–	–	﹤0.01%	1966
2023 Q1	$46.8K	Hold	1,600	–	–	﹤0.01%	1909
2022 Q4	$32	Hold	1,600	–	–	﹤0.01%	1631
2022 Q3	$48K	Sell	1,600 -29	-2%	-$797	﹤0.01%	1836
2022 Q2	$37K	Hold	1,629	–	–	﹤0.01%	2033
2022 Q1	$73K	Hold	1,629	–	–	﹤0.01%	2019
2021 Q4	$63K	Hold	1,629	–	–	﹤0.01%	2065
2021 Q3	$83K	Buy	1,629 +800	+97%	+$40.1K	﹤0.01%	1961
2021 Q2	$72K	Buy	+829	New	+$49.8K	﹤0.01%	1923

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Private Advisor Group's CTXR Position: Q4 2024 in Review

Private Advisor Group sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 1,600 shares — an estimated $20K sold.

Private Advisor Group first reported a position in CTXR in Q2 2021 and held it in 14 quarters. The position peaked at $83K in Q3 2021. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

Private Advisor Group reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Private Advisor Group sold 1,600 Citius Pharmaceuticals shares in Q4 2024, an estimated $20K.
Private Advisor Group first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 14 quarters.
Private Advisor Group's Citius Pharmaceuticals position peaked at $83K in Q3 2021.
30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Private Advisor Group's 13F filing for Q4 2024, filed 3 Feb 2025.